Strategies for the prevention and treatment of statin-induced myopathy: is there a role for ubiquinone supplementation?
Koumis
Tina
T
International Drug Information Center, Arnold & Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, 75 DeKalb Avenue, HS 509, Brooklyn, NY 11201, USA. tina.koumis@liu.edu
Nathan
Joseph P
JP
Rosenberg
Jack M
JM
Cicero
Lorraine A
LA
D008078:Cholesterol, LDL / Q000187:drug effects; D003402:Creatine Kinase / Q000097:blood; D016903:Drug Monitoring / Q000592:standards; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D006949:Hyperlipidemias / Q000188:drug therapy*; D018482:Muscle, Skeletal / Q000187:drug effects; D009135:Muscular Diseases / Q000139:chemically induced* / Q000188:drug therapy / Q000503:physiopathology / Q000517:prevention & control; D017410:Practice Guidelines as Topic; D012206:Rhabdomyolysis / Q000139:chemically induced / Q000188:drug therapy / Q000503:physiopathology / Q000517:prevention & control; D014451:Ubiquinone / Q000097:blood / Q000172:deficiency / Q000627:therapeutic use*
D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D014451:Ubiquinone; D003402:Creatine Kinase